As filed with the Securities and Exchange Commission on February 18, 2009
Registration No. 333-17349
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 1 to Form S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
BARR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 42-1612474
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
400 Chestnut Ridge Road
Woodcliff Lake, New Jersey 07677-7668
(201) 930-3300
(Address of Principal Executive Offices Including Zip Code)
-------------------------------------
Barr Laboratories, Inc. 1993 Stock Incentive Plan
(Full title of the plans)
-------------------------------------
William S. Marth
c/o Teva Pharmaceuticals USA, Inc.
1090 Horsham Road
North Wales, Pennsylvania 19454-1090
(215) 591-3000
(Name, address, including zip code, and telephone number, including area code,
of agent for service)
-------------------------------------
With copies to:
Peter H. Jakes
Jeffrey S. Hochman
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019-6099
(212) 728-8000
-------------------------------------
-------------------------------------
DEREGISTRATION OF UNSOLD SECURITIES
-------------------------------------
The shares of common stock of Barr Pharmaceuticals, Inc., par value $0.01
per share (the "Common Stock"), giving effect to the 3-for-2 stock splits of the
Common Stock in March 2003 and March 2004, previously registered for sale to the
public and remaining unsold under this Registration Statement are hereby
withdrawn from registration.
SIGNATURES
Pursuant to the requirements of the Securities Act, the Company certifies
that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1
to the Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Woodcliff Lake, State of New Jersey,
February 18, 2009.
Barr Pharmaceuticals, LLC, as the
successor entity by merger to
BARR PHARMACEUTICALS, INC.
By: /s/ William S. Marth
-----------------------------------
William S. Marth
President (Chief Executive Officer)
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Post-Effective Amendment No. 1 to the Registration Statement has been
signed by the following persons in the capacities and on the dates indicated.
Name Title(s) Date
---- -------- ----
/s/ William S. Marth President (Chief Executive Officer) and February 18, 2009
--------------------------------- Manager
William S. Marth
/s/ Deborah A. Griffin Chief Financial Officer (Principal Financial February 18, 2009
--------------------------------- Officer and Principal Accounting Officer)
Deborah A. Griffin
/s/ Richard S. Egosi Manager February 18, 2009
---------------------------------
Richard S. Egosi